Cancer risk factors for selecting cohorts for large-scale chemoprevention trials

Journal of Cellular Biochemistry

Volumn 63, Issue SUPPL. 25, 1996, Pages 29-36

  Greenwald, Peter ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

biomarkers; cancer risk assessment; gene environment interactions; large scale trials; prevention trials decision network; twin studies

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; CARBENOXOLONE; COLECALCIFEROL; EFLORNITHINE; FENRETINIDE; FINASTERIDE; GENISTEIN; GLYCYRRHETINIC ACID; IBUPROFEN; OLTIPRAZ; PIROXICAM; PRASTERONE; SELENOMETHIONINE; TAMOXIFEN; TUMOR MARKER; ANTINEOPLASTIC AGENT;

BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DECISION MAKING; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MOLECULAR GENETICS; MOUSE; NONHUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK FACTOR; ANIMAL; DIET; FACTUAL DATABASE; GENETICS; HEALTH CARE ORGANIZATION; METHODOLOGY; NEOPLASM; RAT; TWINS; UNITED STATES;

ANIMALS; ANTICARCINOGENIC AGENTS; CHEMOPREVENTION; CLINICAL TRIALS; DATABASES, FACTUAL; DIET; DISEASES IN TWINS; FEMALE; FENRETINIDE; HUMANS; MALE; MICE; NATIONAL INSTITUTES OF HEALTH (U.S.); NEOPLASMS; RATS; RESEARCH DESIGN; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 0030344932     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4644(1996)25+<29::AID-JCB4>3.0.CO;2-4     Document Type: Review

References (37)

1. Spitz MR, Bondy ML (1993): Genetic susceptibility to cancer. Cancer 72 (Suppl):991-995.
2. Mason E (1970): Obesity in pet dogs. Vet Rec 86:612-616.
3. Deapen D, Escalante A, Weinrib L, Horwitz D, Bachman B, Roy-Burman P, Walker A, Mack TM (1992): A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum 35:311-318.
4. Braun MM, Caporaso NE, Page WF, Hoover RN (1995): A cohort study of twins and cancer. Cancer Epidemiol Biomarkers Prev 4:469-473.
5. Cederlof R, Floderus-Myrhed B (1980): Cancer mortality and morbidity among 23,000 unselected twin pairs. In Gelboin HV (ed): "Genetic and Environmental Factors in Experimental and Human Cancer." Tokyo: Japan Science Society Press, pp 151-160.
6. Gronberg H, Damber L, Damber J-E (1995): Studies of genetic factors in prostate cancer in a twin population. J Urol 152:1484-1489.
7. Kaprio J, Teppo L, Koskenvuo M, Pukkala E (1981): Cancer in adult same-sexed twins: A historical cohort study. Prog Clin Biol Res 69:217-223.
8. Holm NV, Hauge M, Jensen OM (1982): Studies of cancer aetiology in a complete twin population: Breast cancer, colorectal cancer and leukemia. Cancer Surv 1:17-32.
9. Hrubec Z, Neel JV (1982): Contribution of familial factors to the occurrence of cancer before old age in twin veterans. Am J Hum Genet 34:658-671.
10. Easton D, Peto J (1990): The contribution of inherited predisposition to cancer incidence. Cancer Surv 9:395-416.
11. IARC Working Group (1993): "IARC Monographs on the Evaluation of Carcinogenic Risks to Humans (Vol. 56)." Lyon: International Agency for Research on Cancer.
12. Schantz SP, Harrison, LB, Hong WK (1989): Cancers of the head and neck. In: DeVita VT, Jr., Helman S, Rosenberg SA (eds): "Cancer Principles and Practice of Oncology." 4th ed. Philadelphia: J.B. Lippincott, pp 574-672.
13. Mack TM, Cozen W, Shibata DK, Weiss LM, Nathwani BN, Hernandez AM, Taylor CR, Hamilton AS, Deapen DM, Rappaport EB (1995): Concordance for Hodgkin's disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease. N Engl J Med 332:413-418.
14. Diehl V, Tesch H (1995): Hodgkin's disease - environmental or genetic? N Engl J Med 332:461-462.
15. Vianna MD, Greenwald P, Brady J, Polan AK, Dwork A, Mauro J, Davies JNP (1972): Hodgkin's disease: Cases with features of a community outbreak. Ann Intern Med 77:169-180.
16. Burn J, Povey S, Boyd Y, Munro EA, West L, Harper K, Thomas D (1986): Duchenne muscular dystrophy in one of monozygotic twin girls. J Med Genet 23:494-500.
17. Johnson PR, Stern JS, Greenwood MRC, Zucker LM, Hirsch J (1973): Effect of early nutrition on adipose cellularity and pancreatic insulin release in the Zucker rat. J Nutr 103:738-743.
18. Hursting SD, Perkins SN, Phang JM (1994): Calorie restriction delays spontaneous tumorigenesis in p53-knockout transgenic mice. Proc Natl Acad Sci U S A 91:7036-7040.
19. Fodde R, Edelmann W, Yang K, van Leeuwen C, Carlson C, Renault B, Breukel C, Alt E, Lipkin M, Khan PM, Kucherlapati R (1994): A targeted chain-termination mutation in the mouse Apc gene results in multiple intestinal tumors. Proc Natl Acad Sci U S A 91:8969-8973.
20. Lipkin M, Yang K, Fan K, Newmark H, Edelmann W, Fodde R, Leung D, Kucherlapati R (1995): Modulation of colonic lesions induced in Apc 1638 mice by a Western-style diet. Am Assoc Cancer Res Symposium: Cancer Prevention and Intermediate Biomarkers, March 18-22, Abstract.
21. Hursting SD, Perkins SN, Haines DC, Ward JM, Phang JM (1995): Chemoprevention of spontaneous tumorigenesis in p53-knockout mice. Cancer Res 55:3949-3953.
22. Goodman GE (1992): The clinical evaluation of cancer chemoprevention agents: Defining and contrasting phase I, II, and III objectives. Cancer Res 52 (Suppl): 2752s-2757s.
23. Kramer BS, Brawley OW, Nayfield SG, Johnson K, Greenwald P, Ford LG (1993): NCI studies in primary prevention of breast and prostate cancer. Cancer Res Ther Control 3:203-211.
24. Nayfield SG, Karp JE, Ford LG, Dorr FA, Kramer BS (1991): Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 83:1450-1459.
25. Costa A, Formelli F, Chiesa F, Decensi A, De Palo G, Veronesi U (1994): Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res 54 (Suppl):2032s-2037s.
26. De Palo G, Veronesi U, Camerini T, Formelli F (1995): Can fenretinide protect women against ovarian cancer? J Natl Cancer Inst 87:146-147.
27. Ries LAG, Miller BA, Hankey BF, Kosary CL, Harras A, Edwards BK (1994): SEER Cancer Statistics Review, 1973-1991: Tables and graphs. In: "National Cancer Institute NIH Publication No. 94-2789." Bethesda: National Cancer Institute, p 370.
28. Brawley OW, Ford LG, Thompson I, Perlman JA, Kramer BS (1994): 5-α-Reductase inhibition and prostate cancer prevention. Cancer Epidemiol Biomarkers Prev 3:177-182.
29. Kelloff GJ, Boone CW, Steele VE, Crowell JA, Lubet R, Doody LA, Greenwald P (1993): Development of breast cancer chemopreventive drugs. J Cell Biochem 17G (Suppl):2-13.
30. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD (1993): The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 150:379-385.
31. Dhingra K, Vogel V, Sneige N, Sahin A, Aldaz M, Hortobagyi GN, Hittelman W (1993): Strategies for the application of biomarkers for risk assessment and efficacy in breast cancer chemoprevention trials. J Cell Biochem 17G (Suppl):37-43.
32. Kelloff GJ, Crowell JA, Boone CW, Steele VE, Lubet RA, Greenwald P, Alberts DS, Covey JM, Doody LA, Knapp GG, Nayfield S, Parkinson DR, Prasad VK, Prorok PC, Sausville EA, Sigman CC (1994): Clinical development plans for cancer chemopreventive agents: N-(4-hydroxyphenyl)retinamide (4-HPR). J Cell Biochem 20 (Suppl):176-196.
33. Kelloff GJ, Crowell JA, Boone CW, Steele VE, Lubet RA, Greenwald P, Alberts DS, Covey JM, Doody LA, Knapp GG, Nayfield S, Parkinson DR, Prasad VK, Prorok PC, Sausville EA, Sigman CC (1994): Clinical development plans for cancer chemopreventive agents: 2-difluoromethylornithine (DFMO). J Cell Biochem 20 (Suppl):147-165.
34. Lipkin M, Newmark H (1995): Development of clinical chemoprevention trials (editorial). J Natl Cancer Inst 87:1275-1277.
35. Offit K, Brown K (1994): Quantitating familial cancer risk: A resource for clinical oncologists. J Clin Oncol 12:1724-1736.
36. Daly MB (1993): Chemoprevention of cancer: Directions for the future. Cancer Epidemiol Biomarkers Prev 2:509-512.
37. Shields PG, Harris CC (1991): Molecular epidemiology and the genetics of environmental cancer. JAMA 266: 631-687.